Zeist, Netherlands, April 5, 2024 — We’re proud to announce the appointment of Ricard Quingles Blasi as our new Chief Business Officer (CBO). With over 25 years of dynamic leadership experience, Ricard Quingles Blasi brings a wealth of strategic and operational expertise to his new role.

Throughout his career, Ricard Quingles Blasi has demonstrated an exceptional ability to navigate both strategic and operational challenges. His strong track record includes developing high-performing teams and driving sales and profitability across various levels – from local to regional and corporate. Notably, Ricard Quingles Blasi has served as Managing Director for the Southern Europe Region, showcasing his prowess in executive management across multiple functions including Sales, Marketing, Operations, HR, and Finance.

In addition to his executive roles, Ricard Quingles Blasi has assumed P&L responsibility, demonstrating proficiency in managing both top and bottom-line performance. His keen commercial awareness and deep understanding of business drivers have been instrumental in driving growth and success in the organizations he has served.

With international experience that spans living in the USA and leading company growth through organic initiatives, mergers and acquisitions, and strategic partnerships, Ricard Quingles Blasi brings a global perspective to Julius Clinical. He is known for being highly self-motivated, yet a collaborative team player.

Upon his appointment, Ricard Quingles Blasi expressed his enthusiasm, stating, “I’m thrilled to join Julius Clinical where talent and science is within the DNA. I’m looking forward to meeting Julius’ networks of investigators in our different therapeutic areas of expertise, to assist our sponsors in bringing credible scientific advancements to market, thereby enhancing the quality of life for patients worldwide”.

Martijn Wallert, CEO of Julius Clinical, welcomed Ricard Quingles Blasi, stating, “We are very excited to have Ricard on board as our new CBO. With his experience and expertise we will be able to further execute our ambitious growth strategy over the coming years”.

Ricard Quingles Blasi’s appointment marks an exciting chapter for Julius Clinical as the organization continues to expand its capabilities and global presence in clinical research.

For media inquiries, please contact marketing@juliusclinical.com

About Julius Clinical Research

Julius Clinical Research, founded in 2008 and based in Zeist, The Netherlands, is a scientifically focused CRO providing end-to-end clinical trial service to pharmaceutical and biotechnology customers, as well as governments and academia. Julius Clinical’s renowned scientific leaders are at the forefront of their fields, which combine with operational excellence and a global network of research sites to deliver tailor-made solution for customers and their clinical trials. With a focus on the therapeutic areas of neurology, renal, cardiometabolic and infectious diseases, Julius Clinical has grown to approximately 200 employees and has supported over 130 clinical trials, enrolling more than 200,000 participants in around 40 countries. Learn more about Julius Clinical Research at www.juliusclinical.com.